Federal Circuit Upholds Pfizer Patent, Blocks Generic Xalatan

Law360, New York (August 14, 2005, 12:00 AM EDT) -- Pfizer Inc.’s glaucoma drug Xalatan is off limits to generics manufacturer Par Pharmaceutical Inc., following a decision in Pfizer’s favor by the U.S. Court of Appeals for the Federal Circuit.

The initial complaint was filed in December 2001 in the U.S. District Court for New Jersey after Par announced its plans to create a generic version of Xalatan.

Par’s abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) claimed two key patents behind Xalatan invalid, alleging inequitable conduct during the patent application...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.